Financial press releases - Median Technologies

As of December 31, 2021, Median Technologies’ revenue was €20.5 million, a 52% increase compared to 2020 revenue. The order backlog as of December 31, 2021, was €58 million, a €6.3 million increase compared to December 31, 2020 and a €3,8 million increase compared to September 30, 2021. As of December 31, 2021, cash and cash equivalents were €39 million, compared to €16 million as of December 31, 2020.

Under the liquidity contract entrusted by Median Technologies (FR0011049824 – ALMDT FP) to TP ICAP (Europe), the following resources were listed in the liquidity account as of 12/31/2021: 20,093 shares eq. € 231,217.23 in cash.

Disclosure of total number of voting rights and number of shares in the capital as of December 31st, 2021 pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

iBiopsy® Lung Cancer Screening detection performance reaches 94.9% sensitivity for a false positive rate of 1 per CT scan, a performance superior to that of lung CADe systems currently on the market. The particularly high sensitivity of iBiopsy® LCS is a prerequisite for implementing a reliable detection and diagnosis solution for lung cancer screening programs. After detection, the diagnostic component of iBiopsy® LCS characterizes nodules as malignant or benign. Its sensitivity/specificity levels were announced in 2021 and are still unparalleled today.